IN8bio reported that all Acute Myeloid Leukemia patients treated with INB-100 remain in complete remission as of August 2024. The company received FDA guidance for a potential registrational trial and is expanding enrollment to approximately 25 patients. In October 2024, they secured $11.6 million through a private placement, extending cash runway through 2025.The company implemented strategic changes in Q3 2024, including workforce reduction and pipeline prioritization. They suspended enrollment in the Phase 2 INB-400 glioblastoma trial while continuing to monitor existing patients. Q3 financial results showed R&D expenses of $3.3 million (down from $3.8 million YoY) and G&A expenses of $2.7 million (down from $3.4 million YoY).The net loss was $7.1 million ($0.15 per share) compared to $7.2 million ($0.23 per share) in Q3 2023. Cash position stood at $4.0 million as of September 30, 2024, bolstered by the subsequent $11.6 million private placement in October 2024.

IN8bio reported that all Acute Myeloid Leukemia patients treated with INB-100 remain in complete remission as of August 2024. The company received FDA guidance for a potential registrational trial and is expanding enrollment to approximately 25 patients. In October 2024, they secured $11.6 million through a private placement, extending cash runway through 2025.The company implemented strategic changes in Q3 2024, including workforce reduction and pipeline prioritization. They suspended enrollment in the Phase 2 INB-400 glioblastoma trial while continuing to monitor existing patients. Q3 financial results showed R&D expenses of $3.3 million (down from $3.8 million YoY) and G&A expenses of $2.7 million (down from $3.4 million YoY).The net loss was $7.1 million ($0.15 per share) compared to $7.2 million ($0.23 per share) in Q3 2023. Cash position stood at $4.0 million as of September 30, 2024, bolstered by the subsequent $11.6 million private placement in October 2024.